The shingles project is the third vaccine collaboration between the two companies, as they began an influenza vaccine collaboration in 2018 and a COVID-19 vaccine collaboration in 2020, according to a Jan. 5 news release.
The vaccine will be based on BioNTech’s mRNA platform and Pfizer’s antigen technology, the companies said. Under the deal, Pfizer will pay BioNTech $225 million and BioNTech will pay Pfizer $25 million.
The companies expect clinical trials to begin in the second half of 2022.
Read more about the collaboration here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
